Tianyu Mi,Jiawen Yin,Linhai Chen et al.
Tianyu Mi et al.
Introduction: GPR84 is a pro‑inflammatory, metabolite‑sensing Class A GPCR implicated in a range of inflammatory, fibrotic, metabolic, and neuropathic processes. Its inducible expression and role in amplifying innate im...
SLIT2 and ROBO-Axis inhibitors for the treatment of cancer: a patent review (2020-2026) [0.03%]
用于癌症治疗的SLIT2和ROBO轴抑制剂专利回顾（2020-2026）
Mahmoud Khatib Al-Ruweidi,Moustafa T Gabr
Mahmoud Khatib Al-Ruweidi
Introduction: The SLIT2-ROBO signaling axis plays a context-dependent role in cancer, functioning as either a tumor suppressor or oncogenic driver. This bidirectionality creates both therapeutic opportunity and significan...
New insights on anticancer glucocorticoid receptor modulators: a patent review (2020-present) [0.03%]
抗癌糖皮质激素受体调节剂的新见解（2020年至今）——专利回顾
Martina Franzin,Marianna Lucafò,Debora Curci et al.
Martina Franzin et al.
Introduction: Selective glucocorticoid receptor modulators (SGRM) have emerged as promising agents to counteract glucocorticoid‑driven chemoresistance, immune suppression and poor prognosis in solid tumors by modulating ...
An updated review of discoidin domain receptor 1 (DDR1) modulators (2020-present) [0.03%]
Discoidin域受体1(DDR1)调节剂的更新综述(2020年至今)
Yunliang Zhang,Zhen Wang,Ke Ding
Yunliang Zhang
Introduction: As a unique collagen-activated receptor tyrosine kinase, discoidin domain receptor 1 (DDR1) mediates signaling essential for cell proliferation, survival, adhesion, and matrix remodeling. Conversely, its dys...
Recent advances in the discovery of PKMYT1-targeting drugs: a patent review (2021-2025) [0.03%]
近年来蛋白 kinase pkmyt1靶向药物的研发进展：专利盘点（2021-2025）
Yazhou Wang,Chao Wang,Feng Ren et al.
Yazhou Wang et al.
Introduction: PKMYT1, a member of the WEE family of kinases that regulates mitotic entry by phosphorylating CDK1 at Thr14, has recently gained prominence as a promising synthetic lethal target for oncology. Since the firs...
An update on PDGFR inhibitors: a patent review (2020 - present) [0.03%]
血小板源性生长因子受体抑制剂的研发进展（2020年-至今）专利回顾
Sisir Nandi,Sarfaraz Ahmed,Soubhik Barma et al.
Sisir Nandi et al.
Introduction: Platelet-derived growth factor receptors (PDGFRs) play essential roles in cell growth, angiogenesis, and tissue repair, while their dysregulation is implicated in cancer and fibrotic disorders. PDGFR inhibit...
An updated patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2020-2025) [0.03%]
2020-2025年组蛋白脱乙酰酶6抑制剂治疗神经退行性疾病专利回顾及更新
Sida Shen
Sida Shen
Introduction: Histone deacetylase 6 (HDAC6) inhibitors have been widely explored as potential therapeutic approaches for oncological, autoimmune, cardiovascular, and neurodegenerative disorders. Recent clinical advancemen...
Small molecule agonists of Toll-like receptors 7 and 8: an updated patent review 2021 - 2025 [0.03%]
toll-like受体7和8的小分子激动剂（2021-2025）专利回顾更新
Akash M Patel,Natalia Chernyak,W Michael Seganish
Akash M Patel
Introduction: Toll-like receptors 7 (TLR7) and 8 (TLR8) are endosomal receptors that sense single‑stranded RNA and activate MyD88‑dependent inflammatory signaling, linking innate immune detection to adaptive immune resp...
Jiaxing Zhao,Yuxing Li,Wangshan Zheng et al.
Jiaxing Zhao et al.
Introduction: Lysophosphatidic acid receptor 1 (LPAR1), a G protein-coupled receptor, mediates diverse biological effect. Substantial evidence from human patients and experimental models demonstrates that pathological hyp...
Enrico Mario Alessandro Fassi,Marco Albani,Lorenza D&#x;Adduzio et al.
Enrico Mario Alessandro Fassi et al.
Introduction: Proprotein convertase subtilisin/kexin 9 (PCSK9) modulates the circulating levels of low-density lipoprotein cholesterol (LDL-C). Consequently, PCSK9 inhibition, at any level, from the mRNA transcription to ...